110 related articles for article (PubMed ID: 32759572)
1. [Toll-like receptor CD180 and the bone marrow microenvironment as therapeutic targets in multiple myeloma].
Kikuchi J; Furukawa Y
Rinsho Ketsueki; 2020; 61(7):832-841. PubMed ID: 32759572
[TBL] [Abstract][Full Text] [Related]
2. Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide.
Kikuchi J; Kuroda Y; Koyama D; Osada N; Izumi T; Yasui H; Kawase T; Ichinohe T; Furukawa Y
Cancer Res; 2018 Apr; 78(7):1766-1778. PubMed ID: 29363546
[TBL] [Abstract][Full Text] [Related]
3. [Involvement of innate immunity in the expansion of multiple myeloma cells and therapeutic intervention with lenalidomide].
Furukawa Y; Kuroda Y; Kikuchi J
Rinsho Ketsueki; 2018; 59(8):1048-1057. PubMed ID: 30185705
[TBL] [Abstract][Full Text] [Related]
4. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
5. [Epigenetic regulation of cell adhesion-mediated drug resistance acquisition in multiple myeloma].
Furukawa Y; Kikuchi J
Rinsho Ketsueki; 2016 May; 57(5):546-55. PubMed ID: 27263778
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
Kikuchi J; Koyama D; Wada T; Izumi T; Hofgaard PO; Bogen B; Furukawa Y
J Clin Invest; 2015 Oct; 125(12):4375-90. PubMed ID: 26517694
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
[TBL] [Abstract][Full Text] [Related]
9. Correlation of the expression of CD32 and CD180 receptors on CLL cells and MEC1 cell line.
Tsertsvadze T; Mitskevich N; Ghirdaladze D; Porakishvili N
Georgian Med News; 2015 Mar; (240):56-9. PubMed ID: 25879560
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD180, a toll-like receptor homologue, is up-regulated in children with Kawasaki disease.
Imayoshi M; Yamamoto S; Watanabe M; Nishimura S; Tashiro K; Zaitsu M; Tasaki H; Kimoto M; Hamasaki Y; Ishii E
J Mol Med (Berl); 2006 Feb; 84(2):168-74. PubMed ID: 16389554
[TBL] [Abstract][Full Text] [Related]
12. Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway.
Zhou T; Sun Y; Li M; Ding Y; Yin R; Li Z; Xie Q; Bao S; Cai W
Cell Death Dis; 2018 May; 9(6):590. PubMed ID: 29789597
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptors in human multiple myeloma: new insight into inflammation-related pathogenesis.
Abdi J; Garssen J; Redegeld F
Curr Mol Med; 2014 May; 14(4):423-31. PubMed ID: 24730527
[TBL] [Abstract][Full Text] [Related]
14. [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
Kikuchi J; Furukawa Y
Nihon Rinsho; 2015 Jan; 73(1):57-61. PubMed ID: 25626305
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
16. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.
Liu H; He J; Koh SP; Zhong Y; Liu Z; Wang Z; Zhang Y; Li Z; Tam BT; Lin P; Xiao M; Young KH; Amini B; Starbuck MW; Lee HC; Navone NM; Davis RE; Tong Q; Bergsagel PL; Hou J; Yi Q; Orlowski RZ; Gagel RF; Yang J
Sci Transl Med; 2019 May; 11(494):. PubMed ID: 31142679
[TBL] [Abstract][Full Text] [Related]
17. Retinoic acid-induced IgG production in TLR-activated human primary B cells involves ULK1-mediated autophagy.
Eriksen AB; Torgersen ML; Holm KL; Abrahamsen G; Spurkland A; Moskaug JØ; Simonsen A; Blomhoff HK
Autophagy; 2015; 11(3):460-71. PubMed ID: 25749095
[TBL] [Abstract][Full Text] [Related]
18. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
19. Different expression of CD180, CD284 and CD14 receptors on the CD19+ subpopulation of normal and B-CLL lymphocytes.
Antosz H; Sajewicz J; Marzec-Kotarska B; Kocki J; Dmoszyńska A
Folia Histochem Cytobiol; 2009; 47(4):593-8. PubMed ID: 20430725
[TBL] [Abstract][Full Text] [Related]
20. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
